Immuron Limited is excited to announce the official launch of ProIBS®, a product designed to treat the symptoms of Irritable Bowel Syndrome (IBS). We have already received pharmacy orders for this innovative solution, which will join our product portfolio alongside the successful Travelan® brand. ProIBS® is set to provide relief to IBS sufferers, with a particular focus on convenience and efficacy. As IBS affects around 3 out of every 10 people, the potential for ProIBS® in the Australian market is significant. The product has undergone thorough research and development, including a usability study where 94% of users found it helpful. ProIBS® contains AVH200®, derived from Aloe barbadensis, known for its supportive properties for the intestinal mucosal barrier. Our team is dedicated to empowering consumers by offering a safe and effective solution for long-term relief from IBS symptoms. Immuron Limited remains committed to providing innovative solutions for digestive health, and we invite investors to learn more about ProIBS® on our website. Feel free to ask any questions you may have about this exciting development in our product line.